Ticker brief

RARE

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
18
authors 14d
6

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-07-01 · now +0.35 (−1 bearish … +1 bullish)
Who spoke6
authorgradetrader scoresignalsmean sent
@OMillionairesC-1.108+0.37
@semodoughC-0.755+0.37
@OptionsFlowBossC·2+0.22
@MikeJTradesC·1+0.35
@fundmyfundB-2.011+0.40
@Brad_E_SchulzC·1+0.20
Recent signals18of 18 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-07-01@semodough+0.35Says OI traction with FDA would be upside surprise for RARE, though analysts largely ignore it.·
2026-06-30@OMillionaires+0.50Afternoon update reports large percentage gains.·
2026-06-30@OMillionaires+0.35RARE gap filled, next implied.·
2026-06-30@OMillionaires+0.35Bags comment implies bullish excitement on RARE.·
2026-06-30@OMillionaires+0.45RARE filling gaps with bullish money-bag language.·
2026-06-30@Brad_E_Schulz+0.20Midday sector performance overview with bio/pharm and other categories plus percent gainers.·
2026-06-30@fundmyfund+0.40Says many biotech charts including RARE are working in similar setups.·
2026-06-30@semodough+0.50Goldman notes Ph3 GTX-102 data in 2H could translate from Ph1/2 and support filing.·
2026-06-30@semodough+0.35Management discusses FY27 GAAP profitability aided by gene therapy launches and PRVs.·
2026-06-30@OMillionaires+0.35Says RARE tastes better now, implying bullish satisfaction.·
2026-06-29@OMillionaires+0.20Says RARE is on a gap-filling mission.·
2026-06-28@MikeJTrades+0.35stay long RARE though overbought — System says stay long; author notes nice run, overbought, but weekly/monthly charts still rising.·
2026-06-26@OptionsFlowBoss+0.00Mentions OI changes for RARE without direction.·
2026-06-25@OptionsFlowBoss+0.45Reports $425K call buyer in RARE.·
2026-06-25@OMillionaires+0.45Says RARE has gaps to fill at $33.90 then $39.70.·
2026-06-25@OMillionaires+0.35Says RARE is heating up, but limited detail.·
2026-06-23@semodough+0.20Morgan Stanley list of first-in-class 2026 biotech catalysts includes ABVX, CLDX and RARE.·
2026-06-22@semodough+0.45RBC KOL left author incrementally more positive on RARE ahead of pivotal data, but notes 50/50 Phase III risk.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.